Intellia: Intellia to stop work on rare disease therapy, lay off staff
The CRISPR gene editing company will reduce its workforce by 27% over the course of the year as it discontinues a treatment for alpha-1 antitrypsin deficiency.
Read full article »
Intellia Therapeutics is a Massachusetts-based biotechnology company that researches and develops genome editing therapies to treat genetic and oncological diseases.
Read more